Hos 44 patienter > 65 år med skizofreni gav dosering med 5- 20 mg/ dag ingen udsving i bivirkningsprofilen.
In 44 patients with schizophrenia 65 years of age, dosing from 5 to 20 mg/ day was not associated with any distinguishing profile of adverse events.